Actinium Reports New Data Suggesting ATNM-400 May Outperform Blockbuster Prostate Cancer Drugs
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has released preclinical data showing that its experimental therapy, ATNM-400, could offer a powerful new option for men with advanced, treatment-resistant prostate cancer.
Key Highlights
-
Stronger Results than Pluvicto: In animal studies, ATNM-400 significantly improved survival and tumor control compared to Pluvicto®, an FDA-approved radiotherapy with over $1.3 billion in 2024 sales.
-
Effective After Resistance: ATNM-400 remained effective in tumors that had stopped responding to Pluvicto or enzalutamide (Xtandi®).
-
Promising Combo Data: When combined with enzalutamide, 40% of animals experienced complete tumor cures.
-
New Target, New Approach: ATNM-400 targets a protein linked to tumor progression and drug resistance, unlike standard PSMA-focused radiotherapies.
A New Option for Patients with Fewer Choices
Men with advanced prostate cancer often run out of effective treatments. ATNM-400 aims to fill that gap by using Actinium-225 to deliver targeted radiation directly to cancer cells, even in resistant cases.
More data are expected later this year. If results are confirmed in human studies, ATNM-400 could help address a major unmet need in prostate cancer care.
